B+
Bull case
30%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
IOVA
Iovance BiotherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The stock is depressed versus a median analyst target near $9.56 while Iovance now has a commercial product, a visible launch-conversion setup, and multiple registrational shots on goal beyond current melanoma use.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Amtagvi demand may not convert cleanly from center onboarding and Proleukin ordering into sustained infusion volume.
Momentum
100
Value
41
Sentiment
2
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.40 · Bull $6.00 · Bear $2.20Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum100 · Δ7d +0.1
Value41 · Δ7d -0.0
Sentiment2 · Δ7d +1.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Amtagvi demand may not convert cleanly from center onboarding and Proleukin ordering into sustained infusion volume.
- • Board and leadership transition noise remains a background overhang after the March 2026 8-K announcing Wendy Yarno's planned retirement from the board at the June 2026 annual meeting [#8-K-2026-03-20].
- • Evidence quality is only moderate, catalyst density is still low, and the 10-K makes clear the company may need additional capital beyond the next twelve months if commercialization and pipeline spending outrun current resources.
Catalyst clock
2026-06-30
UPS/DDLPS registrational trial start is the clearest near-term pipeline checkpoint
Lead driver: Value · See fundamentals
Momentum
100
9% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
2
62% active weight
Current posture
7d trendImproving
Δ7d
+1.2
Δ21d
-0.9
Why this grade
Composite grade F. Momentum 99.5 / Value 41.2 / Sentiment 2.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$4.40
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.22B
Beta
0.77
Shares Out
452.97M
P/E (TTM) · Derived
-6.5
P/S (TTM)
3.88
P/FCF (TTM) · Derived
-9.68
Rev YoY
+65.7%
EPS YoY
-68.5%
Gross Margin
+37.1%
Op Margin
-91.2%
Net Debt
-$247.54M
Current Ratio
4.34
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data